首页> Cancer chemotherapy and pharmacology> A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.

A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.

导出原文传递

翻译打印收藏纠错

第一作者： Yasushi,Sato

第一单位： Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan. yasushis2012@gmail.com.

作者： Yasushi,Sato ^[1] ; Masahiro,Hirakawa ^[2] ; Hiroyuki,Ohnuma ^[2] ; Minoru,Takahashi ^[3] ; Tetsuro,Okamoto ^[4] ; Koichi,Okamoto ^[5] ; Hiroshi,Miyamoto ^[5] ; Naoki,Muguruma ^[5] ; Tomohisa,Furuhata ^[6] ; Ichiro,Takemasa ^[7] ; Junji,Kato ^[2] ; Tetsuji,Takayama ^[5]

作者单位： Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan. yasushis2012@gmail.com. ^[1] Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan. ^[2] Division of Gastroenterology, Sapporo Kyoritsu Gorinbashi Hospital, Sapporo, Japan. ^[3] Division of Gastroenterology, Kiyota Hospital, Sapporo, Japan. ^[4] Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. ^[5] Department of Gastroenterological Surgery, St. Marianna Medical University Toyoko Hospital, Yokohama, Japan. ^[6] Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo, Japan. ^[7]

关键词 Capecitabine Cetuximab Colorectal cancer Irinotecan Oxaliplatin